Journal
FRONTIERS IN ONCOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1164517
Keywords
liquid biopsy; DLBCL; Hodgkin lymphoma; myeloid neoplasia; precision medicine
Categories
Ask authors/readers for more resources
The assessment of cancer mutational profile is essential for patient management and treatment decisions. Liquid biopsy, specifically analyzing circulating tumor DNA (ctDNA), is an emerging approach that allows genotyping and monitoring of hematological malignancies during therapy and follow-up. It has been shown to capture unique genetic lesions that may be missed by tissue biopsy and predict patient outcomes. Additionally, ctDNA analysis has potential future applications in analyzing DNA fragmentation and epigenetic patterns. Several ongoing clinical trials are incorporating ctDNA analysis for personalized treatment in hematological malignancies.
The assessment of the cancer mutational profile is crucial for patient management, stratification, and therapeutic decisions. At present, in hematological malignancies with a solid mass, such as lymphomas, tumor genomic profiling is generally performed on the tissue biopsy, but the tumor may harbor genetic lesions that are unique to other anatomical compartments. The analysis of circulating tumor DNA (ctDNA) on the liquid biopsy is an emerging approach that allows genotyping and monitoring of the disease during therapy and follow-up. This review presents the different methods for ctDNA analysis and describes the application of liquid biopsy in different hematological malignancies. In diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), ctDNA analysis on the liquid biopsy recapitulates the mutational profile of the tissue biopsy and can identify mutations otherwise absent on the tissue biopsy. In addition, changes in the ctDNA amount after one or two courses of chemotherapy significantly predict patient outcomes. ctDNA analysis has also been tested in myeloid neoplasms with promising results. In addition to mutational analysis, liquid biopsy also carries potential future applications of ctDNA, including the analysis of ctDNA fragmentation and epigenetic patterns. On these grounds, several clinical trials aiming at incorporating ctDNA analysis for treatment tailoring are currently ongoing in hematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available